News & Events

Sarah Hedtrich heads a guest group at the Max Delbrück Center. The Johanna Quandt Professor at the Berlin Institute of Health at Charité (BIH) is working on organ-on-a-chip models to develop new treatment options for rare hereditary and inflammatory skin and lung diseases.

The Robson lab at the Max Delbrück Center will be studying how the 3D structure of chromatin controls genes during development and in disease. Leveraging novel single cell methods, they will look at muscular dystrophies and retinal disease. Both seem to be linked to mutations that disrupt the function of non-coding DNA.

Two science communications projects of the Max Delbrück Center have received funding from the Stiftung Charité. About 100,000 Euro will go to Gary Lewin and illustrator Kat Menschik for a book on unusual animals in research, and to Russ Hodge and Jennifer von Schlichting for a board game on gene expression.

Marta Cipińska coordinates a PhD exchange program between New York University (NYU) and MDC-BIMSB that trains the next generation of systems biologists. No longer a scientist, she has replaced PubMed with browsing the shelves of her local bookstore – and found “Moonwalking with Einstein.”

A Berlin-based team led by ECRC researcher Dominik N. Müller is analyzing how inflammation of the intestinal mucosa affects blood vessels. They are still looking for study participants – especially people with inflammatory bowel diseases, multiple sclerosis, high blood pressure and diabetes.

She wants to uncover the mechanisms behind inflammatory neurodegenerative diseases, while also developing new therapeutic approaches and testing them in clinical trials. With these goals in mind, Frederike Cosima Oertel is launching the Translational Neuroimmunology Lab at the ECRC.

A mutation that causes severe hypertension also protects the kidneys from being damaged, reports a team led by Enno Klußmann of the Max Delbrück Center and the DZHK in “Kidney International”. The researchers are now exploring how the effects of the mutated gene can be used therapeutically.

While CAR-T cells have proven successful in treating certain types of leukemia and lymphoma, these immunotherapies can become even more effective. A clinical trial run by Charité and the Max Delbrück Center has been awarded a grant of several million euros to test a new approach.